Media release
From:
Attachments
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Journal/
conference: JAMA Network Open
conference: JAMA Network Open
Research:Paper
Organisation/s:
McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada
Funder:
The CAHHM was funded by the Canadian Partnership Against Cancer, Heart and Stroke
Foundation of Canada, and the Canadian Institutes of Health Research. Financial contributions were also received
from the Population Health Research Institute and Canadian Institutes of Health Research Foundation grants
FDN-143255 (Dr Anand), FDN-143313 (Jack V. Tu,MD, PhD, MSc, a previous co–principal investigator who has since
died), and FDN-154317 (Dr Smith). In-kind contributionswere made by Sunnybrook Hospital, Toronto, Ontario, for
magnetic resonance imaging reading costs and Bayer AG for provision of intravenous contrast. The Canadian
Partnership for Tomorrow’s Health is funded by the Canadian Partnership Against Cancer, Genome Quebec,
Genome Canada, Ontario Institute for Cancer Research, Government of Alberta, and Alberta Cancer Foundation.
The Prospective Urban Rural Epidemiological (PURE) study was funded by multiple sources. The Montreal Heart
Institute Biobank is funded by André Desmarais and France Chrétien-Desmarais and the Montreal Heart Institute
Foundation. Some of the data used in this research were made available by the Canadian Partnership for
Tomorrow’s Health along with the BC Generations Project, Alberta’s Tomorrow Project, Ontario Health Study,
CARTaGENE, and the Atlantic Partnership for Tomorrow’s Health. Data were harmonized by Maelstrom Research
and access policies and procedureswere developed by the Centre of Genomics and Policy in collaboration with the
cohorts. Dr. Anand holds the Heart and Stroke Foundation Michael G DeGroote Chair in Population Health and a
Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. PURE-Mind Funding: The PURE study is an
investigator-initiated study that was funded by the Population Health Research Institute, Hamilton Health
Sciences Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario,
support from Canadian Institutes of Health Research’s Strategy for Patient Oriented Research, through the Ontario
SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants
from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis
[France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline) and additional
contributions from Novartis and King Pharma and from various national or local organizations in participating
countries. In Canada, there was additional support for the PURE study from an unrestricted grant from Dairy
Farmers of Canada and the National Dairy Council (US), Public Health Agency of Canada, and Champlain
Cardiovascular Disease Prevention Network. The PURE Poland substudy was partially funded by grant 290/WPURE/
2008/0 from the Polish Ministry of Science and Higher Education, and the MRI substudy was supported by
grant NCN 2015/17/B/NZ7-02963 from the Polish National Science Centre.